PMV Pharmaceuticals (PMVP) Competitors $1.49 0.00 (0.00%) As of 02:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMVP vs. GLUE, DMAC, SCPH, CTNM, FDMT, CAPR, FHTX, LFCR, TVRD, and NMRAShould you be buying PMV Pharmaceuticals stock or one of its competitors? The main competitors of PMV Pharmaceuticals include Monte Rosa Therapeutics (GLUE), DiaMedica Therapeutics (DMAC), scPharmaceuticals (SCPH), Contineum Therapeutics (CTNM), 4D Molecular Therapeutics (FDMT), Capricor Therapeutics (CAPR), Foghorn Therapeutics (FHTX), Lifecore Biomedical (LFCR), Tvardi Therapeutics (TVRD), and Neumora Therapeutics (NMRA). These companies are all part of the "pharmaceutical products" industry. PMV Pharmaceuticals vs. Its Competitors Monte Rosa Therapeutics DiaMedica Therapeutics scPharmaceuticals Contineum Therapeutics 4D Molecular Therapeutics Capricor Therapeutics Foghorn Therapeutics Lifecore Biomedical Tvardi Therapeutics Neumora Therapeutics Monte Rosa Therapeutics (NASDAQ:GLUE) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation. Is GLUE or PMVP more profitable? Monte Rosa Therapeutics has a net margin of 13.58% compared to PMV Pharmaceuticals' net margin of 0.00%. Monte Rosa Therapeutics' return on equity of 9.95% beat PMV Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa Therapeutics13.58% 9.95% 6.42% PMV Pharmaceuticals N/A -47.94%-43.82% Which has better valuation & earnings, GLUE or PMVP? PMV Pharmaceuticals has lower revenue, but higher earnings than Monte Rosa Therapeutics. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$75.62M4.09-$72.70M$0.3613.90PMV PharmaceuticalsN/AN/A-$58.71M-$1.57-0.95 Which has more risk & volatility, GLUE or PMVP? Monte Rosa Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Do institutionals and insiders have more ownership in GLUE or PMVP? 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 6.5% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to GLUE or PMVP? In the previous week, Monte Rosa Therapeutics had 2 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 2 mentions for Monte Rosa Therapeutics and 0 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 1.88 beat Monte Rosa Therapeutics' score of 1.14 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Monte Rosa Therapeutics Positive PMV Pharmaceuticals Very Positive Do analysts rate GLUE or PMVP? Monte Rosa Therapeutics presently has a consensus target price of $15.33, indicating a potential upside of 206.36%. PMV Pharmaceuticals has a consensus target price of $5.50, indicating a potential upside of 269.13%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67PMV Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryMonte Rosa Therapeutics and PMV Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Get PMV Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMVP vs. The Competition Export to ExcelMetricPMV PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.96M$2.82B$5.73B$9.81BDividend YieldN/A48.51%6.66%4.48%P/E Ratio-0.9522.6982.3826.51Price / SalesN/A699.07526.77107.89Price / CashN/A26.3325.7028.92Price / Book0.566.8110.636.55Net Income-$58.71M$32.94M$3.28B$266.04M7 Day Performance4.93%0.18%-0.35%-0.79%1 Month Performance6.43%7.61%9.99%6.02%1 Year Performance-5.70%0.06%48.79%21.97% PMV Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMVPPMV Pharmaceuticals3.4556 of 5 stars$1.49flat$5.50+269.1%-5.1%$78.96MN/A-0.9550Positive NewsHigh Trading VolumeGLUEMonte Rosa Therapeutics2.7249 of 5 stars$4.80-0.6%$15.33+219.4%-20.3%$296.45M$75.62M13.3390News CoveragePositive NewsDMACDiaMedica Therapeutics1.5615 of 5 stars$5.71-2.7%$12.33+116.0%+35.4%$295.14MN/A-8.2820News CoverageAnalyst DowngradeSCPHscPharmaceuticals3.9129 of 5 stars$5.50-0.2%$12.00+118.2%+8.3%$293.14M$36.33M-3.0430Short Interest ↑High Trading VolumeCTNMContineum Therapeutics2.6476 of 5 stars$10.45+4.0%$22.75+117.7%-42.7%$293.04M$50M-4.7531Short Interest ↑FDMT4D Molecular Therapeutics2.412 of 5 stars$6.16-0.3%$30.40+393.5%-59.1%$287.69M$40K-1.75120News CoverageCAPRCapricor Therapeutics2.6969 of 5 stars$6.28+0.3%$22.56+259.2%+38.5%$287.10M$22.27M-3.83101Trending NewsFHTXFoghorn Therapeutics2.9796 of 5 stars$5.06+1.0%$10.67+110.8%-36.2%$286.04M$22.60M-4.25120Positive NewsLFCRLifecore Biomedical0.7355 of 5 stars$7.61-0.1%$8.00+5.1%+70.3%$284.67M$128.87M-5.81690Positive NewsTVRDTvardi Therapeutics1.7245 of 5 stars$29.92-1.2%$64.25+114.7%N/A$280.57M$7.14M0.0080Positive NewsNMRANeumora Therapeutics2.9284 of 5 stars$1.73-1.7%$7.14+312.9%-84.9%$280.17MN/A-1.10108Positive NewsShort Interest ↓ Related Companies and Tools Related Companies Monte Rosa Therapeutics Alternatives DiaMedica Therapeutics Alternatives scPharmaceuticals Alternatives Contineum Therapeutics Alternatives 4D Molecular Therapeutics Alternatives Capricor Therapeutics Alternatives Foghorn Therapeutics Alternatives Lifecore Biomedical Alternatives Tvardi Therapeutics Alternatives Neumora Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMVP) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PMVP Stock Alerts